Table 2.
Univariate analysis of mortality among 24 patients with DLI during cetuximab therapy
| Number of patients (of 24) | Number of deaths (of 10) | P value | ||
|---|---|---|---|---|
| Sex | Male | 18 | 7 | 0.6653 |
| Female | 6 | 3 | ||
| Treatment line | Second line | 2 | 1 | 1.000 |
| Third line or later | 22 | 9 | ||
| PS | 0 | 19 | 8 | 1.000 |
| 1 | 5 | 2 | ||
| Combination chemotherapy | Cetuximab alone | 2 | 0 | 0.4928 |
| In combination with CPT-11 or FOLFIRI | 22 | 10 | ||
| Lung metastasis | − | 10 | 5 | 0.6785 |
| + | 14 | 5 | ||
| Classification of images | Diffuse alveolar damage | 8 | 5 | n/a |
| Ground-glass opacity | 14 | 5 | ||
| Unable to be classified | 2 | 0 | ||
| Time to onset of DLI from the start of cetuximab treatment | <90 days | 12 | 8 | 0.0361 |
| ≥91 days | 12 | 2 | ||
| Steroid pulse therapy | − | 10 | 2 | 0.1041 |
| + | 14 | 8 | ||
| Time to the start of steroid pulse therapy from the onset of DLI | Within 3 days | 6 | 2 | 0.2744 |
| 4 days or later | 8 | 6 | ||
| Smoking history | − | 10 | 5 | 1.000 |
| + | 10 | 4 | ||
| Unknown | 4 | 1 |